Dr. Oxnard on Detecting Resistance Mechanisms After Treatment With Osimertinib Dr. Geoffrey R. Oxnard Treating Patients Who Have Become Resistant to EGFR-Inhibitors Cell-free DNA liquid biopsy in lung cancer
Geoffrey Oxnard, MD, of Dana-Farber's Lowe Center for Thoracic Oncology, discuss how a simple blood test may be able to help Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, Dana-Farber Cancer
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss current unmet needs and emerging developments in the use of plasma Liquid Biopsy: Differences Among Technologies Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the recent publication he co-authored in the Annals of
Cell-free DNA sequencing in the clinical setting Upfront EGFR-Targeted Therapy for NSCLC
Geoffrey Oxnard, MD, a thoracic oncologist at Dana-Farber Cancer Institute, led research showing Liquid Biopsy can accurately Foundation Medicine Appoints Dr. Geoffrey Oxnard as Vice The liquid biopsy test is approved to identify patients who may benefit from treatment with specific FDA-approved targeted
Clinical Applications for NSCLC Liquid Biopsy Geoffrey R. Oxnard. Employment: Foundation Medicine. Stock and Other Authors. Affiliations Expand All. Geoffrey R. Oxnard, MD https://orcid. Sandip Patel, MD, and Geoffrey R. Oxnard, MD, explain the strengths and limitations of plasma-based genetic profiling for
Is It Possible to Test Lung Tumors Without Doing a Biopsy? How Liquid Biopsies Help Understanding of Resistance to Chemotherapy
Geoff Oxnard MD (@geoff_oxnard) / Posts / X Geoffrey R Oxnard Geoffrey R. Oxnard, Ryan S. Alden, Cloud P. Paweletz, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston; Kenneth S.
GRACEcastUC 124 Lung_Dr. Oxnard on Repeat Biopsy with Acquired Resistance Targeted Therapy Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of liquid biopsy for identifying resistance Sandip Patel, MD, and Geoffrey R. Oxnard, MD, discuss differences among platforms for genetic profiling of metastatic non–small
Dr. Geoffrey Oxnard describes a study that aims to identify non-smoking lung cancer patients who have a rare EGFR mutation, Acquired Resistance to Osimertinib in T790M-Positive NSCLC Where Do We Go Next with EGFR Inhibitors?
Geoffrey R. Oxnard as vice president, global medical lead for the Company's liquid biopsy portfolio, effective immediately. He joins Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the downfalls of the use of cell-free DNA in the Geoffrey Oxnard | Medicine
Liquid Biopsy for NSCLC: Emerging Developments Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute,
Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the Geoffrey R. Oxnard, MD | Boston Medical Center
Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, explains how genomic Dr. Oxnard Discusses RET Fusions in NSCLC
Geoffrey R. Oxnard, MD Analysis of tumor DNA has transformed cancer care, allowing researchers to identify unique vulnerabilities within some cancers and Sandip Patel, MD, and Geoffrey R. Oxnard, MD, explains how to interpret the results of liquid biopsy results for metastatic Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology,
Cancer detecting and locating: cell-free DNA Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes a wide range of options for best managing Which NSCLC Patients to Recommend Repeat Biopsies with Insufficient Tissue for Molecular Testing
Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, describes which patients with advanced non-small Targeted Treatment for Lung Cancer After Progression
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the use of plasma-based genetic profiling of EGFR and ALK resistance Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
About · Contact. 617.638.7524 · Primary Location. 830 Harrison Ave Moakley 3. Boston, MA 02118. Administrative Title. Associate Professor of Hematology and Final Thoughts
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD, echo the sentiment Impact of COVID-19 on scientific research and treating patients
Geoff Oxnard. BlossomHill Therapeutics, Inc. The University of Chicago Pritzker School of Medicine. Cambridge, Massachusetts, United Is Lung Cancer Hereditary? | Dana-Farber Cancer Institute GRACEcastUC-022_Lung_What is an Inherited T790M EGFR Mutation, and What Does It Mean?
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer The Role for Liquid Biopsy in NSCLC Geoffrey R. Oxnard, MD, assistant professor of Medicine, Dana-Farber Cancer Center, Harvard Medical School, discusses a study
Genetic Testing for NSCLC Geoffrey Oxnard, MD, of Dana-Farber's Lowe Center for Thoracic Oncology, shares his tips for how lung cancer patients can make
Sandip Patel, MD, and Geoffrey R. Oxnard, MD, discuss increased adoption for plasma genotyping in non–small cell lung cancer Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, reviews his thought process in recommending a May 18th Lung Webinar on Molecular Diagnostics in #NSCLC liquid and Tissue NGS.
Geoffrey Oxnard, MD, explains how genomic markers can guide treatment in PD-L1 positive NSCLC Recognizing People Making a Difference in Fighting Cancer
Cell-free DNA for multi-cancer detection At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey Oxnard, MD, from Dana-Farber Cancer
In this episode, Dr. Geoff Oxnard, a thoracic oncologist, discusses his career journey into oncology and shares insights from his Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. In this segment, Mark A. Socinski, MD; Mary Jo Fidler, MD; Roy S. Herbst, MD, PhD; and Geoffrey R. Oxnard, MD, discuss options
Dr. Oxnard Discusses the Circulating Cell-Free Genome Atlas Study Advice for Lung Cancer Patients | Dana-Farber Cancer Institute Geoff Oxnard MD (@geoff_oxnard) - Posts - Drug & diagnostic developer | Thoracic oncology, Boston Medical Center | Husband, father of 4, split.
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the nuances of non–small cell lung cancer mutation testing using TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer How to Understand EGFR T790M Mutations | Dana-Farber Cancer Institute
At the American Society of Clinical Oncology (ASCO) 2012, Geoff Oxnard, MD, discusses how decisions are made about if and Liquid Biopsy and Next-Generation Sequencing
Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, considers whether lorlatinib Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses
Awad, Geoffrey R. Oxnard, David M. Jackman, Jennifer C. Heng, Suzanne E. Dahlberg, Pasi A. Jänne, and Peter S. Hammerman, Dana- Geoffrey R. Oxnard, MD - Google Scholar
Geoffrey R. Oxnard, MD, on the Approval of the FoundationOne Liquid CDx Germline EGFR Mutations and Familial Lung Cancer | Journal of Geoffrey Oxnard, MD, on the FLAURA study impacting treatment selection in EGFR mutant lung cancer
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the choices for genetic testing in metastatic non–small cell lung cancer Geoff Oxnard - BlossomHill Therapeutics, Inc. | LinkedIn Dr. Oxnard, Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, on whether the overall
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer Patient from Hell Ep 62: Transforming Lung Cancer Treatment using Precision Medicine TATTON: Phase 1b trial of combination therapies with AZD9291 in EGFR-mutant lung cancer
Dr. Geoffrey Oxnard from Harvard Medical School talks about EGFR inhibitors and mutations, filmed at IASLC in February 2014. Interpretation of NSCLC Plasma Genotyping Results
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, describe the value of large panel genetic profiling for metastatic non–small cell Four change makers are being awarded for the impact they have made in the fight against cancer. In their first year, the Cancer
Dr. Geoffrey Oxnard from Harvard Medical School talks about EGFR treatment decisions, filmed at IASLC in February 2014. Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will
How a Blood Test Can Find Genetic Abnormalities in Lung Cancer | Dana-Farber Cancer Institute Geoffrey R. Oxnard, MD | Damon Runyon Cancer Research Widespread Mutation Testing for NSCLC
Geoffrey Oxnard, MD, discusses whether lung cancer can be passed down in families, and whether there is are familial risks other MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are
Geoffrey R. Oxnard, MD, and Sandip Patel, MD, discuss the current recommendations for genetic testing in patients with Association Between Plasma Genotyping and Outcomes of
CCGA: plasma cfDNA lung cancer screening How Does Liquid Biopsy Work? Subscribe to the Bio-Rad channel: Geoffrey R. Oxnard,
Geoffrey Oxnard, MD, on the effectiveness of lorlatinib as a frontline agent in ALK+ NSCLC Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, outlines how useful cell-free DNA sequencing will be in the
How Do You Help Your EGFR Patients Make Treatment Decisions When Their Cancers Grow? Lung Cancer Webinar held on May 18, moderated by Hatim Husain, MD UCSD and discussants Joel Neal, MD, Stanford and
Liquid Biopsy study | Dana-Farber Cancer Institute The Pitfalls of cell-free DNA sequencing Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, highlights the impact of COVID-19 on research studies and
Germline EGFR Mutations and Familial Lung Cancer Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest
Plasma Testing for NSCLC EGFR & ALK Mutations Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Dr. Geoffrey Oxnard from Harvard Medical School talks about driver mutation, filmed at IASLC in February 2014. Oncology.
Geoffrey Oxnard, MD, Dana-Farber Cancer Institute, Boston, MA, explains how targeted bisulfite sequencing of plasma cell-free Lung Cancer - interview with Geoff Oxnard, MD, at ASCO 2012
GRACEcastUC-038_Lung_Managing Acq. Resistance to EGFR Therapy (and Probably Crizotinib, Too)